2-arylindoles: A privileged molecular scaffold with potent, broad-ranging pharmacological activity

Current Medicinal Chemistry

Volumn 19, Issue 28, 2012, Pages 4828-4837

  Lal, S ^a   Snape, T J ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

2 arylindoles; Biological activity; Drug discovery; Indoles; Privileged structures

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ACID SENSING ION CHANNEL; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CELECOXIB; COCCIDIOSTATIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; GONADORELIN ANTAGONIST; INDOLE DERIVATIVE; LIVER X RECEPTOR AGONIST; MOLECULAR SCAFFOLD; NEUROKININ 1 RECEPTOR ANTAGONIST; NOCICEPTIN RECEPTOR ANTAGONIST; PROTEIN HISTIDINE KINASE; PROTEIN KINASE C INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACILLUS CEREUS; BACILLUS SUBTILIS; BINDING AFFINITY; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; DRUG POTENCY; EIMERIA TENELLA; EPITHELIUM CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHYSICAL CHEMISTRY; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; APOPTOSIS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; FUNGI; INDOLES; ION CHANNELS; PARASITES;

EID: 84870395663     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803341449     Document Type: Article

References (76)

1. Horton, D.A.; Bourne, G.T.; Smythe, M. L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev., 2003, 103, 893-930.
2. Joshi, K.C.; Chand, P. Biologically active indoles. Pharmazie, 1982, 37(1), 1-12.
3. Sundberg, R.J. Indoles; Academic Press: London, 1996; pp.1-169.
4. Brancale, A.; Silvestri, R. Indole, a core nucleus for potent inhibitors of tubulin polymerization. Med. Res. Rev., 2007, 27(2), 209-238.
5. Martino, G. De; Edler, M. C.; La Regina, G.; Coluccia, A.; Barbera, M.C.; Barrow, D.; Nicholson, R.I.; Chiosis, G.; Brancale, A.; Hamel, E.; Artico, M.; Silvestri, R.. New arylthioindoles: potent inhibitors of tubulin polymerization. 2. structure-activity relationships and molecular modeling studies. J. Med. Chem., 2006, 49, 947-954.
6. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nature Rev. Cancer, 2004, 4, 253-265.
7. Gul, W.; Hamann, M.T. Indole alkaloids marine natural products: an established source of cancer drug leads with considerable promise for the control of parasitic neurological and other diseases. Life Sci., 2005, 78, 442-453.
8. Lake, R.J.; Brennan, M.M.; Blunt, J.W.; Munro, M.H.G.; Pannell, L. K., Eudistomin K sulfoxide- an antiviral sulfoxide from the New Zealand ascidian Ritterella sigillinoides. Tetrahedron Lett., 1998, 29(18), 2255-2256.
9. Tomsaz, M. Mitomycin C: small, fast and deadly (but very selective). Chem. & Biol., 1995, 2, 575-579.
10. Black, W.C.; Bayly, C.; Belley, M.; Chan, C.-C.; Charleson, S.; Denis, D.; Gauthier, J.Y.; Gordon, R.; Guay, D.; Kargman, S.; Lau, C.K.; Leblanc, Y.; Mancini, J.; Ouellet, M.; Percival, D.; Roy, P.; Skorey, K.; Tagari, P.; Vickers, P.; Wong, E.; Xu, L.; Prasit, P., From indomethacin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase- 2 inhibitors. Bioorg. Med. Chem., 1996, 6, 725-730.
11. Buzzi, M.G.; Moskowitz, M.A. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br. J. Pharmacol., 1990, 99, 202-206.
12. Ferrari, M.D.; Saxena, P.R. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol. Sci., 1993, 14, 129-133.
13. Wemmie, J.A.; Price, M.P.; Welsh, M.J. Acid-sensing ion channels: advances, questions and therapeutic opportunities. Trends Neurosci., 2006, 29(10), 578-586.
14. Holzer, P. Acid-sensitive ion channels in gastrointestinal function. Curr. Opin. Pharmacol., 2003, 3, 618-625.
15. Xiong, Z-G.; Pignataro, G.; Li, M.; Chang, S-Y.; Simon, R.P. Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr. Opin. Pharmacol., 2008, 8, 25-32.
16. Mamet, J.; Baron, A.; Lazdunski, M.; Voilley, N. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acidsensing ion channels. J. Neurosci., 2002, 22(24), 10662-10670.
17. Sutherland, S.P.; Benson, C.J.; Adelman, J.P.; McCleskey, E.W. Acidsensing ion channel 3 matches the acid-gated current in cardiac ischaemiasensing neurons. Proc. Natl. Acad. Sci., 2001, 98(2), 711-716.
18. Benson, C.J.; Eckert, S.P.; McCleskey, E.W. Acid-evoked currents in cardiac sensory neurons: a possible mediator of myocardial ischaemic sensation. Circ. Res., 1999, 84, 921-928.
19. Kuduk, S.D; Chang, R.K.; Wai, J.M.-C.; Di Marco, C.N.; Cofre, V.; Di- Pardo, R.M.; Cook, S.P.; Cato, M.J.; Jovanovska, A.; Urban, M.O.; Leitl, M.; Spencer, R.H.; Kane, S.A.; Hartman, G.D.; Bilodeau, M.T., Amidine derived inhibitors of acid-sensing ion channel-3 (ASIC3). Bioorg. Med. Chem. Lett., 2009, 19, 4059-4063.
20. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature, 2000, 406, 775-781.
21. Healy, V.L.; Lessard, I.A.D.; Roper, D.I.; Knox, J.R.; Walsh, C.T. Vancomycin resistance in Enterococci: reprogramming of the D-Ala-D-Ala ligases in bacterial peptidoglycan biosynthesis. Chem. Biol., 2000, 7, 109-119.
22. Kuroda, M.; Ohta, T.; Uchiyama, I.; Baba, T.; Yuzawa, H.; Kobayashi, I.; Cui, L.; Oguchi, A.; Aoki, K.; Nagai, Y.; Lian, J.; Ito, T.; Kanamori, M.; Matsumaru, H.; Maruyama, A.; Murakami, H.; Hosoyama, A.; Mizutani-Ui, Y.; Takahashi, N.K.; Sawano, T.; Inoue, R.; Kaito, C.; Sekimizu, K.; Hirakawa, H.; Kuhara, S.; Goto, S.; Yabuzaki, J.; Kanehisa, M.; Yamashita, A.; Oshima, K.; Furuya, K.; Yoshino, C.; Shiba, T.; Hattori, M.; Ogasawara, N.; Hayashi, H.; Hiramatsu, K. Whole genome sequencing of methicillinresistant Staphylococcus aureus. Lancet, 2001, 357, 1225-1240.
23. Janda, K.D.; Matsushita, M. Histidine kinases as targets for new antimicrobial agents. Bioorg. Med. Chem., 2002, 10, 855-867.
24. Wolanin, P.M.; Thomason, P.A.; Stock, J.B. Histidine protein kinases: key signal transducers outside the animal kingdom. Genome Biology, 2002, 3(10), 3013.1-3013.8.
25. Stock, A.M.; Westand, A.H. Histidine kinases and response regulator proteins in two-component signalling systems. Trends Biochem. Sci., 2001, 26(6), 369-376.
26. Dutta, R.; Qin, L.; Inouye, M. Histidine kinases: diversity of domain organization. Mol. Microbiol., 1999, 34(4), 633-640.
27. Deschenes, R.J.; Lin, H.; Ault, A.D.; Fassler, J.S. Antifungal properties and target evaluation of three putative bacterial Histidine kinase inhibitors. Antimicrob. Agents Chemother., 1999, 43(7), 1700-1703.
28. Leboho, T.C.; Michael, J.P.; van Otterlo, W.A.L.; van Vuuren, S.F.; de Koning, C.B., The synthesis of 2- and 3-aryl indoles and 1,3,4,5- tetrahydropyrano[4, 3-b] indoles and their antibacterial and antifungal activity. Bioorg. Med. Chem. Lett., 2009, 19, 4948-4951.
29. Williams, R.B. A compartmentalised model for the estimation of the cost of coccidiosis to the world's chicken production industry. Int. J. Parasitol., 1999, 29, 1209-1229.
30. Scribner, A.; Moore III, J.A.; Ouvry, G.; Fisher, M.; Wyvratt, M.; Leavitt, P.; Liberator, P.; Gurnett, A.; Brown, C.; Mathew, J.; Thompson, D.; Schmatz, D.; Biftu, T., Synthesis and biological activity of anticoccidial agents: 2, 3- diarylindoles. Bioorg. Med. Chem. Lett., 2009, 19, 1517-1521.
31. Jordan, M.A.; Wilson, L. Nature Rev. Cancer, 2004, 4, 253-265.
32. Hawkins, T.; Mirigian, M; Yasar, M.S.; Ross, J.L. Mechanics of microtubules. J. Biomech., 2010, 43, 23-30.
33. Kaufmann, D.; Pojarová, M.; Vogel, S.; Liebl, R.; Gastpar, R.; Gross, D.; Nishino, T.; Pfaller, T.; von Angerer, E., Antimitotic activities of 2- phenylindole-3-carbaldehydes in human breast cancer cells. Bioorg. Med. Chem., 2007, 15, 5122-5136.
34. Flynn, B.L.; Hamel, E.; Jung, K.M. One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. J. Med. Chem., 2002, 45, 2670-2673.
35. Gastpar, R.; Goldbrunner, M.; Marko, D.; Angerer, E.V. Methoxysubstituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J. Med. Chem., 1998, 41, 4965-4972.
36. Medarde, M.; Ramos, A.C.; Caballero, E.; Peláez-Lamamié de Clairac, R.; López, J.L.; Grávalos, D.G.; Feliciano, A.S. Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg. Med. Chem. Lett., 1999, 9, 2303-2308.
37. Koivunen, J.; Aaltonen, V.; Peltonen, J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. 2006, 235, 1-10.
38. Griner, E.M.; Kazanietz, M.G. Protein kinase C and other diacylglycerol effectors in cancer. Nature Rev. Cancer, 2007, 7, 281-294.
39. Mackay, H.J.; Twelves, C.J. Targeting the protein kinase C family are we there yet? Nature Rev. Cancer, 2007, 7, 554-562.
40. Rumbsy, M.G.; Drew, L.; Warr, J.R. Protein kinases and multidrug resistance. Cytotechnol., 1998, 27, 203-224.
41. Hendricks, R.T.; Sheramn, D.; Strulovici, B.; Broka, C.A. 2-aryl-indolyl maleimides- novel and potent inhibitors of protein kinase C. Bioorg. Med. Chem. Lett., 1995, 5(1), 67-72.
42. FitzGerald, G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Rev. Drug Discov., 2003, 2, 879-890.
43. Hu, W.; Guo, Z.; Chu, F.; Bai, A.; Yi, X.; Cheng, G.; Li, J. Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: a new series of selective COX-2 inhibitors. Bioorg. Med. Chem., 2003, 11, 1153-1160.
44. Marquez, B. Bacterial efflux systems and efflux pump inhibitors. Biochimie., 2005, 87, 1137-1147.
45. Markham, P.N.; Westhaus, E.; Klyachko, K.; Johnson, M.E.; Neyfakh, A.A. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother., 1999, 43(10), 2404-2408.
46. Samosorn, S.; Bremner, J.B.; Ball, A.; Lewis, K. Synthesis of functionalised 2-aryl-5-nitro-1H-indoles and their activity as bacterial NorA efflux pump inhibitors. Bioorg. Med. Chem., 2006, 14, 857-865.
47. Ambrus, J.I.; Kelso, M.J.; Bremner, J.B.; Ball, A.R.; Casadei, G.; Lewis, K. Structure -activity relationships of 2-aryl-1H-indole inhibitors of the NorA efflux pump in Staphylococcus aureus. Bioorg. Med. Chem. Lett., 2008, 18, 4294-4297.
48. Chebib, M.; Johnston, A.R. GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J. Med. Chem., 2000, 43(8), 1427-1447.
49. Falcó, J.L.; Piqué M.; González M.; Buira I.; Méndez E.; Terencio J.; Pérez C.; PrÍncep M.; Palomer A.; Guglietta A., Synthesis, pharmacology and molecular modelling of N-substituted 2-phenyl-indoles and benzimidazoles as potent GABAA agonists. Eur. J. Med. Chem. 2006, 41, 985-990.
50. Auta, J.; Romeo, E.; Kozikowski, A.; Ma, D.; Costa, E.; Guidotti, A. Participation of mitochondrial diazepam binding inhibitor receptors in the anticonflict, antineophobic and anticonvulsant action of 2-aryl-3- indoleacetamide and imidazopyridine derivatives. J. Pharmacol. Exp. Ther., 1993, 265(2), 649-656.
51. Romeo, E.; Auta, J.; Kozikowski, A.; Ma, D.; Papadopoulos, V.; Costa, E.; Guidotti, A. 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J. Pharmacol. Exp. Ther., 1992, 262(3), 971-978.
52. Sealfon, S.C.; Weinstein, H.; Millar, R.P. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr. Rev., 1997, 18(2), 180-205.
53. Chu, L.; Hutchins, J.E.; Weber, A.E.; Lo, J.-L.; Yang, Y.-T.; Cheng, K.; Smith, R.G.; Fisher, M.H.; Wyvratt, M.J.; Goulet, M.T., Initial structureactivity relationship of a novel class of nonpeptidyl GnRH receptor antagonists: 2-arylindoles. Bioorg. Med. Chem. Lett., 2001, 11, 509-513.
54. Chu, L.; Lo, J.-L.; Yang, Y.-T.; Cheng, K.; Smith, R.G.; Fisher, M.H.; Wyvratt, M.J.; Goulet, M.T., SAR studies of novel 5-substituted 2- arylindoles as nonpeptidyl GnRH receptor antagonists. Bioorg. Med. Chem. Lett., 2001, 11, 515-517.
55. Young, J.R.; Huang, S.X.; Walsh, T.F.; Wyvratt, M.J.; Yang, Y.-T.; Yudkovitz, J.B.; Cui, J.; Mount, G.R.; Ren, R.N.; Wu, T.-J.; Shen, X.; Lyons, K.A.; Mao, A.-H.; Carlin, J.R.; Karanam, B.V.; Vincent, S.H.; Cheng, K.; Goulet, M. T. 2-arylindoles as gonadotropin reelasing hormone (GnRH) antagonists: optimization of the tryptamine side chain. Bioorg. Med. Chem. Lett., 2002, 12, 827-832.
56. Tontonoz, P.; Mangelsdorf, D.J. Liver X receptor signalling pathways in cardiovascular disease. Mol. Endocrinol., 2003, 17, 985-993.
57. Bakir, F.; Kher, S.; Pannala, M.; Wilson, N.; Nguyen, T.; Sircar, I.; Takedomi, K.; Fukushima, C.; Zapf, J.; Xu, K.; Zhang, S.-H.; Liu, J.; Morera, L.; Schneider, L.; Sakurai, N.; Jack, R. and Cheng, J.-F., Discovery and structure- activity relationship studies of indole derivatives as liver X receptor (LXR) agonists. Bioorg. Med. Chem. Lett., 2007, 17, 3473-3479.
58. Kher, S.; Lake, K.; Sircar, I.; Pannala, M.; Bakir, F.; Zapf, J.; Xu, K.; Zhang, S.-H.; Liu, J.; Morera, L.; Sakurai, N.; Jack, R.; Cheng, J.-F. 2-Aryl-N-acyl indole derivatives as liver X receptor (LXR) agonists. Bioorg. Med. Chem. Lett., 2007, 17, 4442-4446.
59. Berton, O.; Nestler, E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci., 2006, 7(2), 137-151.
60. Datar, P.; Srivastava, S.; Coutinho, E.; Govil, G. Substance P: structure, function, and therapeutics. Curr. Top. Med. Chem., 2004, 4(1), 75-103.
61. Seward, E.M.; Swain, C.J. Neurokinin receptor antagonists, Expert Opin. Ther. Pat., 1999, 9, 5, 571-582.
62. 1 receptor antagonists: optimisation of indole substitution. Bioorg. Med. Chem. Lett., 2001, 11, 1233-1236.
63. 1 receptor antagonists: optimisation of the 2- aryl ring and the indole nitrogen substituent. Bioorg. Med. Chem. Lett., 2001, 11, 1237-1240.
64. Shaw, D.; Chicchi, G.G.; Elliott, J.M.; Kurtz, M.; Morrison, D.; Ridgill, M.P.; Szeto, N.; Watt, A.P.; Williams, A.R.; Swain, C.J. 2-Aryl indole NK1 antagonists: optimisation of the amide substituent. Bioorg. Med. Chem. Lett., 2001, 11, 3031-3034.
65. Meunier, J.C. Nociceptin/orphanin FQ and the opiod receptor-like ORL1 receptor. Eur. J. Pharm., 1997, 340(1), 1-15.
66. Barlocco, D.; Cignarella, G.; Giardina, G.A.; Toma, L. The opioid-receptorlike 1(ORL-1) as a potential target for new analgesics. Eur. J. Med. Chem., 2000, 35(3), 275-282.
67. Calo' G.; Guerrini, R.; Rizzi, A.; Salvadori, S.; Regoli, D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol., 2000, 129(7), 1261-1283.
68. Sugimoto, Y.; Shimizu, A.; Kato, T.; Satoh, A.; Ozaki, S.; Ohta, H.; Okamoto, O. Design, synthesis, and biological evaluation of indole derivatives as novel nociceptin/orphanin FQ (N/OFQ) receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 3569-3573.
69. Miller, C.P. SERMs: evolutionary chemistry, revolutionary biology. Curr. Pharm. Des., 2002, 8, 2089-2111.
70. Von, Angerer, E.; Prekajac, J.; Strohmeier, J. 2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumour inhibiting activity in the rat. J. Med. Chem., 1984, 27, 1439-1447.
71. Schneider, M.R.; Vonangerer, E.; Hohn, W.; Sinowatz, F. Antitumouractivity of antiestrogenic phenylindoles on experimental prostate tumours. Eur. J. Cancer Clin. Oncol., 1987, 23(7), 1005-1015.
72. Nishino, Y.; Schneider, M.R.; Michna, H.; Angerer, E. Pharmacological characterization of a novel oestrogen antagonist, ZK 119010, in rats and mice. J. Endocrinol., 1991, 130(3), 409-414.
73. von Angerer, E.; Knebel, N.; Ganss, B. 1-(Aminoalkyl)-2-phenylindoles as novel pure estrogen antagonists. J. Med. Chem., 1990, 33, 2635-2640.
74. Miller, C.P.; Collini, M.D.; Tran, B.D.; Harris, H.A.; Kharode, Y.P.; Marzolf, J.T.; Moran, R.A.; Henderson, R.A.; Bender, R.H.W.; Unwalla, R.J.; Greenberger, L.M.; Yardley, J.P.; Abou-Gharbia, M.A.; Lyttle, C.R.; Komm, B.S., Design, synthesis and preclinical characterization of novel, highly selective indole estrogens. J. Med. Chem., 2001, 44, 1654-1657.
75. Greenberger, L.M.; Annable, T.; Collins, K.I.; Komm, B.S.; Lyttle, C.R.; Miller, C.P.; Satyaswaroop, P.G.; Zhang, Y.; Frost, P. A new antiestrogen, 2- (4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1Hindol- 5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifensensitive and resistant tumours and is devoid of uterotropic effects in mice and rats. Clin. Cancer Res., 2001, 7, 3166-3177.
76. Biskobing, D.M. Update on bazedoxifene: a novel selective estrogen receptor modulator. Clin. Inves. Ageing, 2007, 2(3), 299-303.